In vitro cytodestruction of human leukemic cells using murine monoclonal antibodies and human complement.

We have investigated the ability of murine monoclonal antibodies (MoAb) to lyse human leukemic cells in vitro using human serum as a source of complement (C'). The human C'-fixing ability of five of seven MoAb is documented. Studies with two of these MoAb (BA-1 and BA-2) indicated that their human C'-fixing ability and subsequent lysis of leukemic cells was through activation of the classical pathway of C', was independent of donor serum source, and occurred with a number of different target cells. BA-1 and BA-2 could effectively lyse fresh leukemic cells in the presence of 100% human serum, and BA-1 plus human serum could effectively lyse leukemic cells in the presence of a 20-fold excess of normal human bone marrow cells. Our results have potential implications for immunotherapy trials utilizing murine MoAb.

[1]  J. Falkenburg,et al.  Removal of neoplastic cells from autologous bone marrow grafts with monoclonal antibodies. , 1984, Seminars in hematology.

[2]  J. Uhr,et al.  Use of an antibody-ricin A-chain conjugate to delete neoplastic B cells from human bone marrow. , 1983, Blood.

[3]  R. A. Miller,et al.  Tumor therapy with monoclonal antibodies. , 1983, Federation proceedings.

[4]  G. Hale,et al.  Advantages of rat monoclonal antibodies. , 1983, Immunology today.

[5]  D. Boue,et al.  Antibody affinity may influence antigenic modulation of the common acute lymphoblastic leukemia antigen in vitro. , 1982, Journal of immunology.

[6]  M. Borowitz,et al.  Characterization and distribution of a 24,000-molecular weight antigen defined by a monoclonal antibody (DU-ALL-1) elicited to common acute lymphoblastic leukemia (cALL) cells. , 1982, Leukemia research.

[7]  R. Dillman,et al.  Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. , 1982, Blood.

[8]  J. Ritz,et al.  Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. , 1982, Blood.

[9]  K. Foon,et al.  Surface markers on leukemia and lymphoma cells: recent advances. , 1982, Blood.

[10]  S. Sallan,et al.  Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. , 1981, Blood.

[11]  M. Greaves,et al.  P-24: a human leukemia-associated and lymphohemopoietic progenitor cell surface structure identified with monoclonal antibody , 1981, The Journal of experimental medicine.

[12]  T. Lebien,et al.  A monoclonal antibody (BA-1) reactive with cells of human B lymphocyte lineage. , 1981, Journal of immunology.

[13]  M. Greaves,et al.  A monoclonal antibody identifying a cell surface antigen shared by common acute lymphoblastic leukemias and B lineage cells. , 1980, Blood.

[14]  L. Lampson,et al.  Two populations of Ia-like molecules on a human B cell line. , 1980, Journal of immunology.

[15]  R. Hurwitz,et al.  Characterization of a xenoantiserum produced against three molar KCl-solubilized antigens obtained from a non-T, non-B (pre-B) acute lymphoblastic leukemia cell line. , 1979, Journal of immunology.

[16]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[17]  S. Marney,et al.  C3 shunt activation in human serum chelated with EGTA. , 1972, Journal of immunology.

[18]  H. Colten,et al.  Cytotoxic action of antiserum and complement: quantification with a colony inhibition method. , 1971, Immunology.